The compelling biological rationale—whereby TACE provides localized tumor control and antigen release, lenvatinib normalizes tumor vasculature and suppresses immune-suppressive pathways, and PD-1 inhibitors reinvigorate pre-existing antitumor T-cell responses—suggests a potent synergistic effect worthy of investigation in a prospective trial setting. This evidence concerns the gene PDCD1 and neoplasm.